Streetbeat News

Products Services

MORF

Traders are circulating news about Morphic's clinical proof of principle and favorable tolerability profile shown with orally dosed MORF-057 as induction therapy for moderately to severely active UC, according to Phase 2a Emerald-1 study results. Despite the positive news, Morphic's shares are trading lower.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:37 pm

AAPL

Apple Inc has officially launched the iPhone 15, with strong pre-orders and long lines reported in China, Europe, and the U.S. Wedbush analyst Daniel Ives predicts strong market share gains for Apple, with pre-orders tracking 10% to 12% higher than the iPhone 14. Ives also expects strong sales in India and China, and estimates that iPhone units sold could reach 225 million for fiscal 2024. Apple shares are up 1% to $174.93 on Friday.

Portfolio Pulse from Chris Katje

September 22, 2023 | 3:25 pm

DSS

DSS Inc's Global BioLife has been granted Australian Patent Number 2017268240 for 'Electrophilically Enhanced Phenolic Compounds For Treating Inflammatory Related Diseases And Disorders'. This could potentially open new markets and revenue streams for the company.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 3:11 pm

ALPMF

ALPMY

MRK

SGEN

Seagen Inc and Astellas Pharma Inc released positive results from the KEYNOTE-A39 Phase 3 EV-302 trial for Padcev combined with Merck & Co Inc's Keytruda versus chemotherapy in bladder cancer. The trial met its dual primary endpoints of overall survival and progression-free survival compared to chemotherapy. The results are expected to confirm the current U.S. accelerated approval of Keytruda in combination with enfortumab vedotin as first-line treatment for urothelial carcinoma. Seagen's shares are up 3.54% at $213.69.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 3:05 pm

MLGO

MicroAlgo has unveiled a knowledge-enhanced backtracking search algorithm aimed at improving the performance and efficiency of research institutions. This has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 22, 2023 | 2:54 pm

ABAT

BRDS

EXAI

NIO

PINS

Benzinga's Stock Whisper Index highlights five stocks warranting attention for the week of Sept. 22, 2023. These include Nio Inc, which plans to raise $1 billion through convertible senior notes and launch a smartphone for its vehicles; Pinterest, which expects revenue growth in the mid to high teens for the next three to five years and announced a $1 billion share buyback plan; Exscientia Plc, which announced a collaboration with Merck KGaA; Bird Global, which announced the acquisition of Spin; and American Battery Technology, which completed an uplisting from the OTC to the Nasdaq.

Portfolio Pulse from Chris Katje

September 22, 2023 | 2:40 pm

AZN

COTY

EBAY

GOOGL

TSLA

The article covers a range of topics including US markets, crypto, US politics, world politics, electric vehicles, tech, consumer, industrial, energy, and pharma. Key highlights include insider selling of Zoom Video and eBay stocks, Bill Ackman's expectation of a spike in 30-year yields, and the crypto market's reaction to surging bond yields. In the electric vehicle sector, Tesla is making strides in India and facing trading volatility. Tech news includes Google's mocking 'iPager' ad against Apple and Alibaba's use of AI in e-commerce. Coty plans to expand in Europe, and Ford faces scrutiny over engine failure complaints. BP and Shell have a new exploration deal with Trinidad and Tobago, and AstraZeneca's partnered cancer drug meets its primary goal.

Portfolio Pulse from Akanksha Bakshi

September 22, 2023 | 2:33 pm

ESALF

ESALY

MRK

Merck & Co Inc and Eisai Co Ltd have announced that two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima in patients with certain types of metastatic non-small cell lung cancer, did not meet their primary endpoints. The safety profiles of the treatment regimens were consistent with previous studies. Keytruda plus Lenvima is approved in the U.S., the EU, Japan, and other countries for advanced renal cell carcinoma and certain types of advanced endometrial carcinoma.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 2:21 pm

BMY

Bristol Myers Squibb & Co (NYSE:BMY) announced that its lead cancer drug, Opdivo, met its primary goal in a Phase 3 lung cancer study. The trial showed a significant improvement in event-free survival (EFS) compared to neoadjuvant chemotherapy and placebo. The company plans to share the results at an upcoming medical conference and discuss with health authorities.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 2:18 pm

Toyota Motor Corporation (NYSE:TM) plans to accelerate the production of electric vehicles (EVs) for its Toyota and Lexus brands, aiming to reach an annual output of over 600,000 vehicles by 2025. The company initially targeted sales of 1.5 million EVs yearly by 2026 and 3.5 million by 2030. Toyota is also working on its prototype equipment for the Giga casting technology, which improves the quality of castings and reduces the number of defective products.

Portfolio Pulse from Nabaparna Bhattacharya

September 22, 2023 | 2:16 pm